Kelly D.F. Hagman
Sr. Director, Clinical Diagnostics, Ambry Genetics
Kelly Hagman, MS, CGC, is the VP of Medical Affairs at Ambry Genetics. Prior to Kelly’s 20 year career in molecular diagnostic laboratories, she spent several years in a research lab studying DNA mutagenesis and sequencing technologies. She started her career as a genetic counselor at the Molecular Diagnostic Laboratory at City of Hope, where […]
Kelly Hagman is senior director of clinical diagnostics at Ambry Genetics. Prior to Kelly’s 17 year career in molecular diagnostic laboratories, she spent several years in a research lab studying DNA mutagenesis and sequencing technologies. She started her career as a genetic counselor at the Molecular Diagnostic Laboratory at City of Hope, where she continued her involvement in research and is the corresponding author on one of the most highly referenced Li-Fraumeni Syndrome (LFS) papers (Gonzalez et al, JCO 2009 PMID: 18632684). Driven by her passion for new and emerging molecular technologies, in 2009 Kelly joined Ambry Genetics as the Director of the Genomic Services Division where she gained expertise in multiple sequencing platforms and DNA/RNA enrichment techniques. In 2011, she was chosen to lead the launch the very first commercially-offered diagnostic exome sequencing test on the market. Kelly currently directs Ambry’s rare disease reporting. Her passion for molecular technologies led her to co-found NSGC’s Genomic Technology Special Interest Group (SIG). She was selected as NSGC’s liaison to the Association for Molecular (AMP) for their NGS Germline Variant Confirmation working group. Kelly is also a firm believer that the best patient care is achieved through open data sharing. She has more than 50 peer-reviewed publications in molecular genetics and genomics, most focusing on exome sequencing.
(https://www.ncbi.nlm.nih.gov/sites/myncbi/1rGP7EbZoVMAS/bibliography/48799477/public/?sort=date&direction=ascending)